OST-122 / Oncostellae - LARVOL DELTA

TOWARD A SAFER, NON-SYSTEMIC JAK INHIBITOR FOR IBD: A PHASE 2A STUDY TO EVALUATE SAFETY, PHARMACOKINETICS AND PRELIMINAR CLINICAL EFFICACY OF ORAL TREATMENT WITH OST-122 IN PATIENTS WITH ULCERATIVE COLITIS (UEGW 2024) - "GI-restricted OST-122 was well tolerated during the 4-week treatment. Its excellent safety profile, minimal systemic exposure and promising trends of clinical activity may provide a safer therapeutic option for a broad range of ulcerative colitis patients."

Clinical • P2a data • PK/PD data • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Bowel Disease • Ulcerative Colitis • IL12A • JAK3 • TYK2

Evaluation of safety, pharmacokinetics and efficacy of oral treatment with OST-122 in patients with moderate to severe ulcerative colitis: A Phase Ib/IIa, randomized, double blind, placebo controlled clinical trial (ECCO-IBD 2024) - "Conclusion GI-restricted OST-122 was well tolerated during the 4-week treatment. Its excellent safety profile, limited systemic absorption and promising trends of clinical activity may provide a safer therapeutic option for patients with moderate to severe UC."

Clinical • P1/2 data • PK/PD data • Immunology • Inflammatory Bowel Disease • Ulcerative Colitis • IL12A • JAK3 • TYK2

Study of OST-122 in Patients With Moderate to Severe Ulcerative Colitis (clinicaltrials.gov) - P1/2 | N=32 | Completed | Sponsor: Oncostellae S.L | Recruiting ➔ Completed

Trial completion • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Bowel Disease • Ulcerative Colitis • CRP • TNFA

Study of OST-122 in Patients With Moderate to Severe Ulcerative Colitis (clinicaltrials.gov) - P1/2 | N=32 | Recruiting | Sponsor: Oncostellae S.L | Trial primary completion date: May 2022 ➔ Nov 2022

Trial primary completion date • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Bowel Disease • Ulcerative Colitis • CRP • TNFA

Study of OST-122 in Patients With Moderate to Severe Ulcerative Colitis (clinicaltrials.gov) - P1/2; N=32; Recruiting; Sponsor: Oncostellae S.L; Trial completion date: Apr 2022 ➔ Nov 2022

Clinical • Trial completion date • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Bowel Disease • Ulcerative Colitis • CRP • TNFA

Study of OST-122 in Patients With Moderate to Severe Ulcerative Colitis (clinicaltrials.gov) - P1/2; N=32; Recruiting; Sponsor: Oncostellae S.L; Trial completion date: Dec 2021 ➔ Apr 2022

Clinical • Trial completion date • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Bowel Disease • Ulcerative Colitis • CRP • TNFA

Study of OST-122 in Patients With Moderate to Severe Ulcerative Colitis (clinicaltrials.gov) - P1/2; N=32; Recruiting; Sponsor: Oncostellae S.L; Not yet recruiting ➔ Recruiting; Initiation date: May 2020 ➔ Oct 2020; Trial primary completion date: May 2021 ➔ Dec 2021

Clinical • Enrollment open • Trial initiation date • Trial primary completion date • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Bowel Disease • Ulcerative Colitis • CRP • TNFA

Study of OST-122 in Patients With Moderate to Severe Ulcerative Colitis (clinicaltrials.gov) - P1/2; N=32; Not yet recruiting; Sponsor: Oncostellae S.L

Clinical • New P1/2 trial • Gastroenterology • Immunology • Inflammation • Inflammatory Bowel Disease • Ulcerative Colitis